Murray Honick, MD
Psychiatry · Myrtle Beach, SCNPI 1932183357
Payments from drug & device makers
Across 644 payments — averaging $194.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$85K
- Ironshore Pharmaceuticals Inc.$33K
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$788
- Otsuka America Pharmaceutical, Inc.$585
- Corium, LLC$570
- plus $4K from 21 others
What the payments were for
- Speaking & faculty fees$102,45082%
- Travel & lodging$12,51810%
- Food & beverage$10,2688%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 171 | $85,028 |
| Ironshore Pharmaceuticals Inc. | 92 | $33,300 |
| AbbVie(2 entities) | 97 | $1,091 |
| Sunovion Pharmaceuticals Inc. | 38 | $788 |
| Otsuka America Pharmaceutical, Inc. | 21 | $585 |
| Corium, LLC | 27 | $570 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $490 |
| Johnson & Johnson | 20 | $448 |
| Lundbeck LLC | 24 | $441 |
| Teva Pharmaceuticals USA, Inc. | 19 | $417 |
| Adlon Therapeutics L.p. | 17 | $306 |
| Neurocrine Biosciences, Inc. | 14 | $284 |
| Alkermes, Inc. | 11 | $211 |
| Axsome Therapeutics, Inc. | 9 | $197 |
| Tris Pharma Inc | 11 | $189 |
| Vanda Pharmaceuticals Inc. | 7 | $173 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $138 |
| Bausch Health US, LLC | 7 | $115 |
| Avanir Pharmaceuticals, Inc. | 5 | $106 |
| Jazz Pharmaceuticals Inc. | 4 | $87 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $85 |
| Shire North American Group Inc | 3 | $53 |
| Indivior Inc. | 3 | $53 |
| Neos Therapeutics, LP | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$78,264
- Jornay PM 20mg capsules (Bottle of 100)$22,747
- JORNAY PM$8,911
- LATUDA$223
- REXULTI$201
- VRAYLAR$123
- INVEGA SUSTENNA$114
- INVEGA TRINZA$114
How this compares
$125,236 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 22 | $42,638 |
| CaplytaLumateperone Tosylate | 13 | $27,493 |
| TrintellixVortioxetine Hydrobromide | 41 | $24,711 |
| Duloxetine Hcl | 153 | $8,913 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 267 | $8,764 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $8,212 |
| Lisdexamfetamine Dimesylate | 31 | $6,637 |
| Quetiapine Fumarate | 58 | $4,444 |
| Bupropion XlBupropion Hcl | 88 | $3,625 |
| Aripiprazole | 134 | $3,483 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 43 | $3,256 |
| Alprazolam | 287 | $3,167 |
| Vilazodone Hcl | 41 | $2,751 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 32 | $2,560 |
| Bupropion Hcl SrBupropion Hcl | 92 | $2,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $585 | $42,63822 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $490 | $32,92362 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $138 | $27,49313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Myrtle Beach
- Adedapo OduwoleMyrtle Beach$56K
- Jacobo MintzerCharleston$4.9M
- Paul RobbinsSummerville$1.2M
- Brittany AlbrightMount Pleasant$691K
- Eduardo CifuentesCharleston$675K
- Veronica RidpathFlorence$364K
- Mark GeorgeCharleston$332K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.